Standard BioTools Inc.
2.00
-0.06 (-2.91%)
At close: Jan 14, 2025, 3:59 PM
2.01
0.25%
After-hours Jan 14, 2025, 04:25 PM EST
undefined%
Bid 1.91
Market Cap 746.38M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.87
PE Ratio (ttm) -2.3
Forward PE n/a
Analyst Buy
Ask 2.01
Volume 1,843,025
Avg. Volume (20D) 1,885,577
Open 2.05
Previous Close 2.06
Day's Range 1.93 - 2.05
52-Week Range 1.21 - 3.04
Beta undefined

About LAB

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immu...

Sector Healthcare
IPO Date Feb 10, 2011
Employees 534
Stock Exchange NASDAQ
Ticker Symbol LAB

Analyst Forecast

According to 2 analyst ratings, the average rating for LAB stock is "Buy." The 12-month stock price forecast is $2.88, which is an increase of 43.64% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Standard BioTools Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $47.03M, reflecting a 66.84% YoY growth and earnings per share of -0.08, making a -68.00% decrease YoY.
1 day ago · Source
+26.38%
Standard BioTools shares are trading higher after ... Unlock content with Pro Subscription
5 months ago · Source
-36.61%
Standard BioTools shares are trading lower after the company reported worse-than-expected Q2 financial results and cut FY24 revenue guidance below estimates. The company announced CFO Jeffery Black will resign.